Status:
UNKNOWN
Percentage of BRAFV600E Alleles and Outcome in Thyroid Carcinoma
Lead Sponsor:
University of Salerno
Conditions:
Papillary Thyroid Cancer
Eligibility:
All Genders
18+ years
Brief Summary
BRAFV600E is the most frequent oncogene in Papillary thyroid carcinoma (PTC). It correlates with greater extension, lymph node metastasis, and advanced stage. However, the prognostic value of BRAFV600...
Detailed Description
BACKGROUND Papillary thyroid carcinoma (PTC) generally shows an excellent prognosis with a 5-year survival of over 95%. Even when PTC metastasizes to the regional lymph nodes, a frequent occurrence, i...
Eligibility Criteria
Inclusion
- Patients undergone surgery because of any PTC subtypes 3 years before or more
- Availability of PTC tissue samples, well annotated
- Availability of clinical data of the patients including gender, age at diagnosis, type and extension of surgery, radiation therapy, radio-iodide therapy, TSH suppressive therapy
- Follow up of 3 years or more after surgery, including periodical 6 months assessment of TSH, thyroglobulin and AbTG, neck ultrasound evaluation and episodic hrTSH stimulation test
Exclusion
- Inadequate tissue samples or clinical data and follow up
- Purity of PTC samples \< 50%
Key Trial Info
Start Date :
February 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 30 2021
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04664413
Start Date
February 1 2021
End Date
May 30 2021
Last Update
December 14 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Medicine and Surgery, Univeristy of Salerno
Baronissi, Salerno, Italy, 84081